By: IPP Bureau
Last updated : December 22, 2023 9:06 am
Natco Pharma Limited vide its disclosure dated 8th September 2023 has informed that Celgene Corporation, Bristol Myers Squibb Company, Breckenridge Pharmaceutical and Natco Pharma Limited have been named defendants in an antitrust lawsuit in the US by Louisiana Health Service & Indemnity Company D/B/A Blue Cross and Blue Shield of Louisiana and HMO Louisiana, regarding Pomalidomide (POMALYST) capsules.
The plaintiffs voluntarily dismissed Breckenridge Pharmaceutical and Natco Pharma Limited from the case. All claims against the company in the litigation have now been dismissed.
Breckenridge is the ANDA holder and front-end marketing partner for the Pomalidomide capsules generic product in the US.
Natco's Pomalidomide capsules generic product has not yet launched in the US.